

# FY25 AGM

NOVEMBER 27, 2025









# **CEO'S ADDRESS**

SAMANTHA CHEETHAM





## **FY25 PERFORMANCE HIGHLIGHTS**

Improved operational efficiencies continue to drive strong margin growth

#### **FINANCIAL**

Revenue of \$110.4m (- 0.7% pcp)

62.9% Gross Profit Margin (+80 bps)

EBITDA \$21.3m (-2.7% pcp)

**Dividend 1.90 cps (Unchanged)** 

Normalised NPAT \$10.5m (+0.1% pcp)



#### **BUSINESS**

Revenue flat with mix of regional performance

New machinery, product and geographical mix boosts gross margin

Further operational efficiencies as new machines are fully utilized


**New branding and product launches** 

New site works to begin


## SALES BY BUSINESS UNIT

#### Good European and Brazilian Growth offset by weaker Direct Exports

#### SALES BY BUSINESS UNIT (AUD MILLIONS)



#### **BUSINESS UNIT % SALES**




——Australian sales (incl. direct exports) ——North America ——Europe ——Brazil

#### FY24 SALES GROWTH BY BUSINESS UNIT (% on PCP)


| Business Unit                    | \$m (AUD) | Change (AUD) % | Change (Local) % | Total (AUD) % | Comment  |
|----------------------------------|-----------|----------------|------------------|---------------|--|
| Australia (incl. direct exports) | 32.8      | -9.7           | -10.5            | 29.7          | Australian sales (incl direct exports), were down by 10.5%, with Direct exports down 15.3%, when adjusted for currency movements.        |
| North America                    | 24.3      | -1.5           | -3.0             | 22.0          | North American sales down 3.0% in local currencies, primarily due to a 16.6% decline in Amalgam sales.                                   |
| Europe                           | 44.6      | 8.0            | 5.8              | 40.5          | European sales were up 5.8% in local currencies, driven by demand for Aesthetic products in most European markets.                       |
| Brazil                           | 8.6       | -2.6           | 9.7              | 7.8           | Brazilian sales up 9.7% in local currencies, due to Distributors returning to normal business after reducing their inventory in the pcp. |
| TOTAL                            | 110.4     | -0.7           | -1.2             | 100.0         |  |

## SALES BY PRODUCT CATEGORY

#### Aesthetics & Whitening continued strength with Amalgam declines continuing



#### **CATEGORY AS % SALES**



| Product category | \$m (AUD) | Change (AUD) % | Change (Local) % | Comments  |
|------------------|-----------|----------------|------------------|---|
| Aesthetics       | 57.8      | 4.5            | 4.0              | Aesthetics sales continued to show good growth, up 4.0%. Sales increased across all regions partly offset by a decline in Australian direct export with sales down 10.2%.               |
| Whitening        | 32.0      | 3.2            | 2.0              | Whitening sales increased by 2.0% with good increases in the North American and Australian domestic markets.  |
| Equipment        | 6.2       | -5.1           | -2.2             | Equipment sales, largely a complimentary product, fell 2.2%, reflecting a decrease in all markets, apart from Brazil and Europe which saw strong increases 4.4% and 18.3% respectively. |
| Amalgam          | 14.4      | -21.5          | -21.9            | Amalgam sales decreased by 21.9%, reflecting significant declines in most market  |
|                  |           |                |                  |   |

### PROJECT MONTROSE

- Montrose Project Update
  - Construction tenders received around \$26 million
  - Due diligence in progress on preferred tender.
  - The planning permit has been received.
  - The project will be fully funded by a combination of sale and lease back of the current Bayswater premises and debt.




## PROJECT MONTROSE

Final Design completed

Tendering Works Stage Completed March 2026 – Contract Signed, Commence Construction

March 2027 – Commence Relocation








Dec 2027 – Relocation Completed





### SDI – ESG ROADMAP

**FY25** "Complying"

- Review top suppliers on ESG risks and incorporate into an updated Modern Slavery
  Statement
- Conduct an internal climatic risk assessment
- Commence reporting in-line with mandatory Climate-related financial disclosure standards (AASB S2)\*
- Perform a waste audit/review to
   discover packaging recyclability
   and reduction opportunities
- Publish inaugural ESG report



"Enhancing"

- Review initiatives for emission reduction actions/strategies, including how this reflects on a new efficient facility
- Assess progress on relevant
   SDGs, review those selected
- Review ESG governance and resources, reset goals, objectives and targets (new ESG Roadmap)
- Review diversity of workforce and board composition
- Publish iterative ESG
   Report, which includes the requirements of the AASB S2\*

# Additional ESG actions completed in FY25

- AASB S2 Gap Analysis
- ESG Scorecard
- AASB S2 Climate Reporting Roadmap
- ESG Policy

\*For climate-related financial disclosures, IFRS S2 is replaced by ASRS AASB S2 for Australian reporting purposes.

### **STRATEGY**

### **PRIORITY 1**

# High quality market leading products

SDI will focus its sales, marketing and innovation efforts on its Riva, composites, cements and Pola brands. This targeted innovation will deliver incremental sales growth and act as a gateway to introduce clinicians to SDI's full portfolio.

### **PRIORITY 2**

#### **Business Excellence**

Overall continuous improvement will increase the efficiency and effectiveness of SDI processes and supply chains. Increasing output and lowering costs will ensure SDI remains competitive and compliant with local and international regulations.

### **PRIORITY 3**

# Premium positioning and awareness

Increasing the awareness and quality perception of SDI is pivotal to achieving short-term and long-term growth.

## STRATEGY & OUTLOOK

- Aesthetics and Whitening products continue to be the focus for new product development
  - Stela exceeding expectations, on track to be one of our best product launches
- Achieve manufacturing and logistic efficiencies through new site to help achieve sales of +\$200m
- Investment in production automation
- On-going investment in research and development
  - Release to the market of 1 to 2 new products in the next 12 months



# AWARDS













## **Important Notice & Disclaimer**

This Presentation contains summary information about SDI Limited (SDI) and its subsidiaries and their activities. The information in this Presentation does not purport to be complete. It should be read in conjunction with SDI's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at www.asx.com.au.

The information contained in this Presentation is not investment or financial product advice and has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek independent professional advice appropriate to their jurisdiction and circumstances.

To the extent permitted by law, no responsibility for any loss arising in any way from anyone acting or refraining from acting as a result of this information is accepted by SDI, any of its related bodies corporate or its Directors, officers, employees, professional advisors and agents (Related Parties). No representation or warranty, express or implied, is made by any person, including SDI and its Related Parties, as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this Presentation.

An investment in SDI securities is subject to investment and other known and unknown risks, some of which are beyond the control of SDI or its Directors. SDI does not guarantee any particular rate of return or the performance of SDI securities.

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. This Presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of SDI and associated entities of SDI and certain plans and objectives of the management of SDI. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of SDI to be materially different from the results or performance expressed or implied by such forward-looking statements.

Such forward-looking statements are based on numerous assumptions regarding SDI's present and future business strategies and the political, regulatory and economic environment in which SDI will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation or warranty is made that any of these statements or forecasts (express or implied) will come to pass or that any forecast result will be achieved.

Forward-looking statements speak only as at the date of this Presentation and to the full extent permitted by law, SDI and its Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this Presentation (including, but not limited to, any assumptions or expectations set out in this Presentation).

Statutory profit is prepared in accordance with the Corporations Act 2001 and the Australian Accounting Standards, which comply with the International Financial Reporting Standards (IFRS). Underlying profit is categorised as non-IFRS financial information and therefore has been presented in compliance with Australian Securities and Investments Commission Regulatory Guide 230 – Disclosing non-IFRS information, issued in December 2011.

All figures in this Presentation are A\$ unless stated otherwise and all market shares are estimates only. A number of figures, amounts, percentages, estimates, calculations of value and fractions are subject to the effect of rounding. Accordingly, the actual calculations of these figures may differ from figures set out in this Presentation.